158 related articles for article (PubMed ID: 8428330)
1. Deferred therapy in patients with advanced disease.
Smith PH
Cancer; 1993 Feb; 71(3 Suppl):1074-7. PubMed ID: 8428330
[TBL] [Abstract][Full Text] [Related]
2. [Androgen deprivation for advanced prostate cancer].
Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
[TBL] [Abstract][Full Text] [Related]
3. [Current treatment of locally advanced and metastatic prostate cancer].
Ponholzer A; Steinbacher F; Madersbacher S; Schramek P
Wien Med Wochenschr; 2011 Aug; 161(15-16):377-81. PubMed ID: 21953428
[TBL] [Abstract][Full Text] [Related]
4. [What is safe in the therapy of advanced prostatic cancer?].
Gropp C; Burk K
Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
[No Abstract] [Full Text] [Related]
5. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
6. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
7. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
8. Maximal androgen ablation: a review.
Miles BJ; Babiarz J
Henry Ford Hosp Med J; 1992; 40(1-2):114-7. PubMed ID: 1428961
[TBL] [Abstract][Full Text] [Related]
9. Complete androgen blockade for the treatment of prostate cancer.
Labrie F; Dupont A; Belanger A
Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
[No Abstract] [Full Text] [Related]
10. Timing of androgen deprivation for prostate cancer: benefits versus side effects--a patient-physician dialogue.
Soloway MS
Urology; 2002 Nov; 60(5):735-7. PubMed ID: 12429286
[No Abstract] [Full Text] [Related]
11. Relapse on endocrine treatment in patients with stage D2 prostate cancer. Does second-line hormonal therapy affect survival?
Matzkin H; Rangel MC; Soloway MS
Urology; 1993 Feb; 41(2):144-8. PubMed ID: 8497986
[TBL] [Abstract][Full Text] [Related]
12. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
Carroll PR; Kantoff PW; Balk SP; Brown MA; D'amico AV; George DJ; Grossfeld GD; Johnson CS; Kelly WK; Klotz L; Lee WR; Lubeck DP; Mcleod DG; Oh WK; Pollack A; Sartor O; Smith MR; Hart C;
Urology; 2002 Sep; 60(3 Suppl 1):1-6. PubMed ID: 12231036
[No Abstract] [Full Text] [Related]
13. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate.
Seay TM; Blute MC; Zincke H
Urology; 1997 Dec; 50(6):833-7. PubMed ID: 9426709
[No Abstract] [Full Text] [Related]
14. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
15. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MA; Piulats JM; Sánchez-Hernández A; Arranz JÁ; Cassinello J; García-Donas J; González del Alba A; León-Mateos L; Mellado B; Méndez-Vidal MJ; Pérez-Valderrama B;
Crit Rev Oncol Hematol; 2012 Sep; 83(3):341-52. PubMed ID: 22285697
[TBL] [Abstract][Full Text] [Related]
16. Validation and development of the CHAARTED criteria in patients with hormone-naïve metastatic prostate cancer: A multi-institutional retrospective study in Japan.
Okamoto T; Hatakeyama S; Narita S; Arai Y; Habuchi T; Ohyama C
Int J Urol; 2020 Jan; 27(1):90-91. PubMed ID: 31617248
[No Abstract] [Full Text] [Related]
17. The patient, disease status, and treatment options for prostate cancer: stages D1 and D2.
Schmidt JD
Prostate; 1983; 4(5):493-501. PubMed ID: 6351040
[TBL] [Abstract][Full Text] [Related]
18. Prostatic cancer: are we closer to rational treatment selection?
Scher HI
Curr Opin Oncol; 1992 Jun; 4(3):442-54. PubMed ID: 1379831
[TBL] [Abstract][Full Text] [Related]
19. Advanced prostate cancer: what's new in hormonal manipulation?
Brewster SF; Gillatt DA
Br J Hosp Med; 1993 May 19-Jun 1; 49(10):710-1, 714-5. PubMed ID: 7686805
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy.
Labrie F; Belanger A; Simard J; Labrie C; Dupont A
Cancer; 1993 Feb; 71(3 Suppl):1059-67. PubMed ID: 8428328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
